Viridian Therapeutics, Inc. (NASDAQ:VRDN) COO Purchases $117,050.00 in Stock

Viridian Therapeutics, Inc. (NASDAQ:VRDN) COO Thomas W. Beetham bought 5,000 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were bought at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the transaction, the chief operating officer now directly owns 6,000 shares of the company’s stock, valued at $140,460. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Viridian Therapeutics Stock Down 2.5 %

Shares of VRDN stock traded down $0.58 on Monday, hitting $22.75. The company’s stock had a trading volume of 868,145 shares, compared to its average volume of 1,142,569. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -5.18 and a beta of 1.03. Viridian Therapeutics, Inc. has a fifty-two week low of $10.93 and a fifty-two week high of $24.18. The firm’s fifty day moving average price is $16.99 and its 200-day moving average price is $15.20. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.82 and a quick ratio of 15.82.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.09 million. Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. Research analysts anticipate that Viridian Therapeutics, Inc. will post -3.94 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on VRDN. Wedbush reissued an “outperform” rating and issued a $42.00 price target on shares of Viridian Therapeutics in a research note on Monday, July 29th. BTIG Research lifted their target price on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank of Canada restated an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research report on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and set a $27.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, September 10th. Finally, Needham & Company LLC increased their target price on Viridian Therapeutics from $30.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.80.

Institutional Investors Weigh In On Viridian Therapeutics

A number of large investors have recently added to or reduced their stakes in VRDN. Ameritas Investment Partners Inc. raised its position in shares of Viridian Therapeutics by 19.2% in the first quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after purchasing an additional 799 shares during the period. Principal Financial Group Inc. raised its holdings in Viridian Therapeutics by 9.7% in the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after acquiring an additional 1,058 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in Viridian Therapeutics by 4.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after acquiring an additional 1,135 shares during the last quarter. Arizona State Retirement System boosted its holdings in Viridian Therapeutics by 14.7% during the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock valued at $171,000 after acquiring an additional 1,688 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Viridian Therapeutics by 24.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after purchasing an additional 2,359 shares during the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.